Where does Klaus Veitinger work?

Klaus Veitinger is Venture Partner at OrbiMed and Board director at Alpheus Medical and Board director at Sparrow Pharma and Board director at Tricida.

What does Klaus Veitinger invest in?

Klaus Veitinger invests in Biotech.

What check size does Klaus Veitinger write?

Klaus Veitinger typically writes checks of $1M – $75M.

What boards does Klaus Veitinger sit on?

Klaus Veitinger holds tracked board seats at Alpheus Medical, Neurogastrx, Promentis Pharmaceuticals, Sparrow Pharma, Symbiomix Therapeutics, Tricida.

Where did Klaus Veitinger go to school?

Klaus Veitinger studied at Heidelberg University (Doctor of Medicine (M.D.)); INSEAD (Master of Business Administration (MBA)).

Klaus Veitinger

Investor

Venture Partner at OrbiMed · Board director at Alpheus Medical · Board director at Sparrow Pharma · Board director at Tricida

New York, New York

Writes $1M – $75M checks · typically $4M

Find your path to Klaus

271 people in our graph share verified history with Klaus — schools, employers, funds. One of them is your warm intro.

René KuijtenunlockedKlaus: together at INSEAD (1994)

Klaus: together at Neurogastrx

×2Klaus: together at INSEAD

×2Klaus: together at Sparrow Pharma

About

Klaus Veitinger joined OrbiMed in 2007 as a Venture Partner, focusing on venture investments in therapeutics, and has held board roles at various OrbiMed portfolio companies. He previously served as CEO of Schwarz Pharma Inc., overseeing its U.S. and Asia businesses through the sale of the Schwarz Group, and spent seven years as a Director of PhRMA. He holds a medical degree and Ph.D. from the University of Heidelberg and an M.B.A. from INSEAD.

Invests in

Biotech

Board director at Alpheus Medical

Intro paths

→

In turn, Klaus can intro founders to Alpheus Medical's investors below.

Alpheus Medical's investors · 5

Action Potential Venture Capital Ltd.Scotts Valley · since 2025 HealthQuest CapitalRedwood City OrbiMedNew York · $1M – $75M checks · since 2025 Samsara BioCapitalPalo Alto SV Health InvestorsBoston · $1M – $20M checks

Board director at Sparrow Pharma

Intro paths

→

In turn, Klaus can intro founders to Sparrow Pharma's investors below.

Sparrow Pharma's investors · 4

OrbiMedNew York · $1M – $75M checks · since 2025 RA CapitalBoston RiverVest Venture PartnersSt. Louis · $500K – $3M checks · since 2025 US Venture PartnersMenlo Park · $500K – $10M checks

Board director at Tricida

Intro paths

→

In turn, Klaus can intro founders to Tricida's investors below.

Tricida's investors · 5

Avoro Capital AdvisorsNew York Frazier Life SciencesPalo Alto · since 2021 Longitude CapitalMenlo Park · $10M – $30M checks OrbiMedNew York · $1M – $75M checks · since 2016 Wellington ManagementBoston · $5M – $50M checks

Co-founders at Tricida

Gerrit KlaernerExecutive Officer, Director

Experience

OrbiMedVenture Partnercurrent2007 — presentNew York, United States
Helicore BiopharmaExecutive Chairmancurrent2024 — present
Sparrow Pharmaceuticals, Inc.Chairman of the Boardcurrent2021 — present
Alpheus Medical, IncExecutive Chairmancurrent2020 — present
FDA - Brain Cancer Research RoundtableInvestor Representativecurrent2021 — present
Cure Rare DiseaseBoard Membercurrent2024 — present
Alliance for Cancer Gene TherapyBoard Membercurrent2020 — present
scPharmaceuticalsBoard Member2017 — 2025
Neurogastrx, Inc.Chairman of the Board2017 — 2025
Tricida, Inc.Chairman of the Board2013 — 2023South San Francisco, California, United States
Symbiomix Therapeutics, LLCCEO2014 — 2017
Intercept PharmaceuticalsBoard Member2012 — 2016
RELYPSA, INC.Vice Chairman of the Board2010 — 2015
Synageva BioPharma Corp.Board Member2007 — 2008
Schwarz Pharma Inc.CEO1998 — 2006
AnorMEDVice Chairman of the Board2006

Skills & more

CEOVenture Capital

From Klaus's professional profile.

Deals · 4

Alpheus MedicalBoard seat

via OrbiMed · filed Jul 2026 · $67M raise

Promentis PharmaceuticalsBoard seat

via OrbiMed · filed Dec 2019 · $6M raise

TricidaBoard seat

via OrbiMed · filed Jul 2016 · $55.5M raise

Symbiomix TherapeuticsBoard seat

via OrbiMed · filed May 2016 · $6M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Neurogastrx Sparrow Pharma

Per SEC Form D filings.

Colleagues at OrbiMed

Aldo Brambilla

Associate at Silver Lake Partners

Alexander M. Cooper

Investor at OrbiMed

Anat Naschitz

Executive Officer at OrbiMed

Anat Nursella

Venture Partner at OrbiMed

Andrew P. Kanarek, CFA, CIPM

Investor at Insight Partners

Network1

Daniel Coley

Associate at Cofounders Capital

Investors connected to Klaus in public investor directories — a warm-intro map.

Frequently asked questions

Who is Klaus Veitinger?: Klaus Veitinger joined OrbiMed in 2007 as a Venture Partner, focusing on venture investments in therapeutics, and has held board roles at various OrbiMed portfolio companies. He previously served as CEO of Schwarz Pharma Inc., overseeing its U.S. and Asia businesses through the sale of the Schwarz Group, and spent seven years as a Director of PhRMA. He holds a medical degree and Ph.D. from the University of Heidelberg and an M.B.A. from INSEAD.
Where does Klaus Veitinger work?: Klaus Veitinger is Venture Partner at OrbiMed and Board director at Alpheus Medical and Board director at Sparrow Pharma and Board director at Tricida.
What does Klaus Veitinger invest in?: Klaus Veitinger invests in Biotech.
What check size does Klaus Veitinger write?: Klaus Veitinger typically writes checks of $1M – $75M.
What boards does Klaus Veitinger sit on?: Klaus Veitinger holds tracked board seats at Alpheus Medical, Neurogastrx, Promentis Pharmaceuticals, Sparrow Pharma, Symbiomix Therapeutics, Tricida.
Where did Klaus Veitinger go to school?: Klaus Veitinger studied at Heidelberg University (Doctor of Medicine (M.D.)); INSEAD (Master of Business Administration (MBA)).